About Worldwide  |     FAQs    |    Careers    |        Media Center  |    Taj Pharmaceuticals  World   |    TAJ Group
       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Amlodipine Maleate

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
     
 
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
   



 

 

 

 

 

 












 

 

Amlodipine Maleate   Cas o. 88150-47-4g
Chemical Formulas

Amlodipine Maleate  Molecular Formula  C20H25ClN2O5.C4H4O4;C24H29ClN2O9

 
                                     Identification

Name             :     Amlodipine maleate
Synonyms             2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
                              3- ethyl 5-methyl ester (Z)-2-butenedio
.

Molecular Formula       C20H25ClN2O5.C4H4O4;C24H29ClN2O9
Molecular Weight         524.95 CAS
Registry Number           88150-47-4



Amlodipine Maleate Description

Amlodipine besylate is the besylate salt of Amlodipine, a long-acting calcium channel blocker.

Amlodipine besylate is chemically described as 3-Ethyl-5-methyl ()-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its molecular formula is C20H25CIN2O5C6H6O3S, and its structural formula is:

Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that Amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.
             
Cosopt lowers high pressure in the eye, a problem typically caused by the condition known as open-angle glaucoma. Cosopt works by reducing production of the liquid that fills the eyeball.


Norvasc does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving Norvasc and concomitant beta-blockers. In clinical studies in which Norvasc was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, Norvasc therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.






 

 


                       
PDF DOWNLOAD     
Taj pharmaceuticals API Logo

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

      Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.